ConductScience.org, home

Paper42136641

Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.

Horenstein AL and 4 others. Front Immunol, 2026. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective. Papers, record 42136641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42136641

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.
PubMed
Journal
Front Immunol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2026-08-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Horenstein ALAlberto L
2Frerichs KAKristine A
3Faini ACAngelo C
4van de Donk NWCJNiels W C J
5Malavasi FFabio

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
ADP-ribosyl Cyclase 1Major topic
Antibodies, MonoclonalMajor topic
ImmunotherapyMajor topic
Membrane GlycoproteinsMajor topic
Antineoplastic Agents, ImmunologicalMajor topic
Humans
Adenosine
NAD
Cell Line, Tumor
Inosine
Animals
GPI-Linked Proteins
Antibodies, Monoclonal, Humanized

Source PubMed

Download CSV of topics

References105

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122969159The membrane-bound enzyme CD38 exists in two opposing orientations.Sci Signal2012https://conductscience.org/library/papers/22969159PubMed
237418547The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.Sci Immunol2023https://conductscience.org/library/papers/37418547PubMed
329719225A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline.Cell Metab2018https://conductscience.org/library/papers/29719225PubMed
427316683The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.J Immunol2016https://conductscience.org/library/papers/27316683PubMed
527307294CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.Blood2016https://conductscience.org/library/papers/27307294PubMed
626903141The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias.Cell Signal2016https://conductscience.org/library/papers/26903141PubMed
731350295The Tumor Microenvironment Innately Modulates Cancer Progression.Cancer Res2019https://conductscience.org/library/papers/31350295PubMed
840632830Potential functions of TRPM2 and TRPM7 channels in the tumor microenvironment.J Leukoc Biol2025https://conductscience.org/library/papers/40632830PubMed
939364393Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.Clin Transl Immunology2024https://conductscience.org/library/papers/39364393PubMed
1034625791Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma.Blood Adv2021https://conductscience.org/library/papers/34625791PubMed
1139985195Targeting the Adenosine-Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo-Immunotherapy.Adv Sci (Weinh)2025https://conductscience.org/library/papers/39985195PubMed
129748331The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries.Biochemistry1998https://conductscience.org/library/papers/9748331PubMed
1332844992The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.Blood2020https://conductscience.org/library/papers/32844992PubMed
1421187443Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.J Immunol2011https://conductscience.org/library/papers/21187443PubMed
1530359421Accurate measurement of endogenous adenosine in human blood.PLoS One2018https://conductscience.org/library/papers/30359421PubMed
1628373875Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche.Front Immunol2017https://conductscience.org/library/papers/28373875PubMed
1732049008Prebiotic-Induced Anti-tumor Immunity Attenuates Tumor Growth.Cell Rep2020https://conductscience.org/library/papers/32049008PubMed
1838464531Different evasion strategies in multiple myeloma.Front Immunol2024https://conductscience.org/library/papers/38464531PubMed
1933096610The Circular Life of Human CD38: From Basic Science to Clinics and Back.Molecules2020https://conductscience.org/library/papers/33096610PubMed
2023420183Multiple myeloma-initiating cells.Int J Hematol2013https://conductscience.org/library/papers/23420183PubMed

See all 105 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42724012Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Front Immunol2026https://conductscience.org/library/papers/42724012PubMed
42709393Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression.Cell Biochem Biophys2026https://conductscience.org/library/papers/42709393PubMed
42608642Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.BioDrugs2026https://conductscience.org/library/papers/42608642PubMed
42587741Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling.Cells2026https://conductscience.org/library/papers/42587741PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADA100PubTator's text mininghttps://conductscience.org/library/genes/100NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
NT5E4907PubTator's text mininghttps://conductscience.org/library/genes/4907NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42136641

GET https://conductscience.org/api/papers/v1/42136641/references?page=2